Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-23T14:21:54.486Z Has data issue: false hasContentIssue false
  • English
  • Français

Second generation antipsychotics: evolution of scientific knowledge or uncovering fraud

Published online by Cambridge University Press:  07 February 2013

R. Rosenheck
R. Rosenheck*
Affiliation:
Yale Department of Psychiatry and VA New England Mental Illness, Research, Education and Clinical Center, West Haven, CT, USA
*
Address for correspondence: Professor Robert Rosenheck, VA Connecticut Health Care System, 950 Campbell Avenue, Building 35, West Haven, CT 06516, USA. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Antipsychotic drugsschizophreniapsychopharmacologypharmaceutical marketing
Type
Commentaries
Information
Epidemiology and Psychiatric Sciences , Volume 22 , Issue 3 , September 2013 , pp. 235 - 237
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Almashat, S, Preston, C, Waterman, T, Wolfe, S, Public Citizen's Health Research Group (2010). Rapidly Increasing Criminal and Civil Monetary Penalties Against the Pharmaceutical Industry: 1991 to 2010. Retrieved 12 October 2011 from http://www.citizen.org/documents/rapidlyincreasingcriminalandcivilpenalties.pdfGoogle Scholar
Breier, A (2011). Anxiety disorders and antipsychotic drugs: A pressing need for more research. American Journal of Psychiatry 168, 1012–1014.Google Scholar
Berenson, A (2006). Eli Lilly Said to Play Down Risk of Top Pill. New York Times, 17 December 2006. Retrieved 12 October 2011 from http://www.nytimes.com/2006/12/17/business/17drug.html?pagewanted=allGoogle Scholar
Business Week (2012a). Arkansas judge fines J&J $1.1B in Risperdal case. Business Week, April 2012. Retrieved 30 October 2011 from http://www.businessweek.com/ap/2012-04/D9U31A8O1.htmGoogle Scholar
Business Week (2012b). J&J Said to Agree to $2.2 Billion Drug Marketing Accord. Business Week, June 2012. Retrieved 30 October 2011 from http://www.businessweek.com/news/2012-06-11/j-and-j-said-to-pay-2-dot-2-billion-to-end-risperdal-sales-probeGoogle Scholar
Comer, JS, Mojtabai, R, Olfson, M (2011). National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. American Journal of Psychiatry 168, 1057–1065Google Scholar
Hausman, K (2009). Industry-supported symposia to be phased out. Psychiatry News 44, 4.CrossRefGoogle Scholar
IMS Health, 2012. http://www.imshealth.com/ims/Global/Content/Corporate/Press%20Room/Top-line%20Market%20Data/2008%20Top-line%20Market%20Data/Global_Top_15_Therapy_Classes.pdfGoogle Scholar
Leslie, D & Rosenheck, RA (2012). Off-label use of antipsychotic medications in Medicaid. American Journal of Managed Care 18, e109–e117.Google Scholar
Leslie, DL, Mohamed, S, Rosenheck, RA (2009). Off-label use of antipsychotic medications in the Department of Veterans Affairs. Psychiatric Services 60, 1175–1181.Google Scholar
Lewis, DA, Michels, R, Pine, DS, Schultz, SK, Tamminga, CA, Freedman, R (2006). Conflict of interest. American Journal of Psychiatry 163, 571–573.CrossRefGoogle ScholarPubMed
Rosenheck, RA (2005). The growth of psychopharmacology in the 1990s: evidence-based practice or irrational exuberance. International Journal of Law and Psychiatry 28, 467–483.CrossRefGoogle ScholarPubMed
Rosenheck, R, Perlick, D, Bingham, S, Liu-Mares, W, Collins, J, Warren, S, Leslie, D, Allan, E, Campbell, EC, Caroff, S, Corwin, J, Davis, L, Douyon, R, Dunn, L, Evans, D, Frecska, E, Grabowski, J, Graeber, D, Herz, L, Kwon, K, Lawson, W, Mena, F, Sheikh, J, Smelson, D, Smith-Gamble, V; Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. Journal of the American Medical Association 290, 2693–2702.CrossRefGoogle ScholarPubMed
Tollefson, GD, Beasley, CM Jr, Tran, PV, Street, JS, Krueger, JA, Tamura, RN, Graffeo, KA, Thieme, ME (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 154, 457–465.Google ScholarPubMed
US Department of Justice (2009). Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa. Retrieved 30 October 2012 from http://www.justice.gov/opa/pr/2009/January/09-civ-038.htmlGoogle Scholar